137 related articles for article (PubMed ID: 19945056)
1. Targeting heart failure therapeutics: a historical perspective.
Murphy GA; Fiuzat M; Bristow MR
Heart Fail Clin; 2010 Jan; 6(1):11-23. PubMed ID: 19945056
[TBL] [Abstract][Full Text] [Related]
2. Renin-angiotensin gene polymorphisms and neurohormonal inhibition.
Pauly DF
Heart Fail Clin; 2010 Jan; 6(1):25-6. PubMed ID: 19945057
[TBL] [Abstract][Full Text] [Related]
3. The sympathetic nervous system in heart failure physiology, pathophysiology, and clinical implications.
Triposkiadis F; Karayannis G; Giamouzis G; Skoularigis J; Louridas G; Butler J
J Am Coll Cardiol; 2009 Nov; 54(19):1747-62. PubMed ID: 19874988
[TBL] [Abstract][Full Text] [Related]
4. [Development of heart failure in the course of coronary artery disease--the role of genetic factors].
Kozieradzka A; Kamiński K; Musiał WJ
Kardiol Pol; 2005 Oct; 63(4 Suppl 2):S440-9. PubMed ID: 20527399
[TBL] [Abstract][Full Text] [Related]
5. Pharmacogenomics for neurohormonal intervention in heart failure.
McNamara DM
Heart Fail Clin; 2005 Apr; 1(1):141-50. PubMed ID: 17386840
[No Abstract] [Full Text] [Related]
6. Genomic variation and neurohormonal intervention in heart failure.
McNamara DM
Heart Fail Clin; 2010 Jan; 6(1):35-43. PubMed ID: 19945059
[TBL] [Abstract][Full Text] [Related]
7. Peptides as targets for antihypertensive drug development.
Hedner T; Sun X; Junggren IL; Pettersson A; Edvinsson L
J Hypertens Suppl; 1992 Dec; 10(7):S121-32. PubMed ID: 1291647
[TBL] [Abstract][Full Text] [Related]
8. Genetic predisposition to heart failure.
Pasotti M; Repetto A; Tavazzi L; Arbustini E
Med Clin North Am; 2004 Sep; 88(5):1173-92. PubMed ID: 15331312
[TBL] [Abstract][Full Text] [Related]
9. Compensatory changes of sympathetic tone, the renin-angiotensin-aldosterone system, vasopressin, and ANF as potential therapeutic targets in congestive heart failure.
van Zwieten PA
Z Kardiol; 1988; 77 Suppl 5():67-76. PubMed ID: 2975894
[TBL] [Abstract][Full Text] [Related]
10. [Neurohormonal factors in heart failure. II].
Cosín Aguilar J; Cruz Fernández JM; de Teresa Galván E; Ferreira Montero IJ; López-Sendón J; Soler Soler J; Tamargo Menéndez J
Rev Esp Cardiol; 1996 May; 49(5):317-27. PubMed ID: 8744385
[TBL] [Abstract][Full Text] [Related]
11. [Neurohormonal activation in congestive heart failure: does it normalize after heart transplantation?].
Pérez-Villa F; Roig E; Ferrer E; Cuppoletti A; Llancaqueo M; Jiménez W; Sanz G
Rev Esp Cardiol; 2004 Aug; 57(8):725-31. PubMed ID: 15282060
[TBL] [Abstract][Full Text] [Related]
12. Treatment of congestive heart failure in the elderly: emphasis on renal functional changes and impact of therapy.
Chau WL; Burnett JC
Coron Artery Dis; 1997; 8(8-9):505-9. PubMed ID: 9431478
[TBL] [Abstract][Full Text] [Related]
13. Pharmacologic management of heart failure: neurohormonal agents.
Moser DK
Crit Care Nurs Clin North Am; 1993 Dec; 5(4):599-608. PubMed ID: 7905275
[TBL] [Abstract][Full Text] [Related]
14. [Neurohormonal factors in heart failure (and III)].
Cosín Aguilar J; Cruz Fernández JM; de Teresa Galván E; Ferreira Montero IJ; López-Sendón J; Soler Soler J; Tamargo Menéndez J
Rev Esp Cardiol; 1996 Jun; 49(6):405-22. PubMed ID: 8753906
[TBL] [Abstract][Full Text] [Related]
15. Neurohormonal activation and the response to converting enzyme inhibitors in congestive heart failure.
Kubo SH
Circulation; 1990 Feb; 81(2 Suppl):III107-14. PubMed ID: 2137052
[TBL] [Abstract][Full Text] [Related]
16. Circulating tumor necrosis factor-alpha levels in chronic heart failure: relation to its soluble receptor II, interleukin-6, and neurohumoral variables.
Koller-Strametz J; Pacher R; Frey B; Kos T; Woloszczuk W; Stanek B
J Heart Lung Transplant; 1998 Apr; 17(4):356-62. PubMed ID: 9588580
[TBL] [Abstract][Full Text] [Related]
17. [Neurohormonal factors in heart failure. I].
Cosín Aguilar J; Cruz Fernández JM; de Teresa Galván E; Ferreira Montero IJ; López-Sendón J; Soler Soler J; Tamargo Menéndez J
Rev Esp Cardiol; 1996 Apr; 49(4):239-52. PubMed ID: 8650399
[TBL] [Abstract][Full Text] [Related]
18. [A comparative study of cardiac function in transgenic hypertensive rats, in spontaneously hypertensive rats and in normotensive rats].
Bohlender J; Hildenbrand U; Schlegel WP; Hempel P; Nissen E; Krause EG; Bartel S
Arch Mal Coeur Vaiss; 2000 Aug; 93(8):993-6. PubMed ID: 10989744
[TBL] [Abstract][Full Text] [Related]
19. Suppression of the renin-angiotensin-aldosterone system in chronic heart failure: choice of agents and clinical impact.
Jorde UP
Cardiol Rev; 2006; 14(2):81-7. PubMed ID: 16493245
[TBL] [Abstract][Full Text] [Related]
20. [Neuroendocrine activation in heart failure I. Pathophysiology and pharmacological intervention].
Kjaer A
Ugeskr Laeger; 2000 Oct; 162(44):5905-9. PubMed ID: 11094549
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
